A blueprint for high-volume, high-quality lung cancer screening that is detecting cancer earlier—and helping to save lives
“Adherence is a behavioral issue,” says Bob Nease, chief science officer at Express Scripts. And inadequate adherence is so widespread that the World Health Organization estimates that half of all patients do not take their medications properly. Yet few efforts to improve compliance are specifically designed to help people overcome internal barriers.
The obstacles vary so widely that no single approach can be effective. Stephen Wegener, PhD, a psychologist and associate professor in physical medicine and rehabilitation at Johns Hopkins University School of Medicine, studies noncompliance. He has described four categories of underlying impediments to adherence:
Access. Taking a medication presumes the patient saw a doctor, received a diagnosis, and was able to fill a prescription. “But some people may have trouble getting to a pharmacy and live in an area without delivery options,” Wegener says. Others hesitate to fill a prescription if their insurance does not cover the medication.
Knowledge. A patient may not understand all the instructions for how to take this particular drug, or may not fully grasp exactly what the medication is for, which limits the motivation to take it.
Cognition. Sometimes a patient with faulty memory simply doesn’t remember to take the medication on time or exactly as directed.
Behavior. “Any number of comorbidities can influence medication-taking,” Wegener says. Depression might lead to feeling, “Why bother? Who cares?” Anxiety about side effects can interfere. “It could make me gain weight” is a common deterrent, as are warnings about other unpleasant possibilities, like constipation. “Some people take too little medication because they are afraid of addiction. The fewer the side effects, the higher the adherence,” he reports.
Now, several ambitious projects are tackling adherence-related behavioral problems.
At Thomas Jefferson University Hospital in Philadelphia, a “Heart Failure Readmission Reduction” pilot program began in November 2010 with 436 patients. The multidiscipline, low-cost education program — utilizing binders, online information, videos, phone calls, and frequent in-person contact with a cardiac nurse — was created to reduce heart failure readmission rates of Medicare patients. Readmission is important to payers because of substantial penalties to be imposed by the Centers for Medicare & Medicaid Services.
A main component is patient and family education, built around a binder that includes weight control, diet, and exercise materials; basic medical information; a medication log where patients review the medications they are supposed to take and when they are to take them; and discharge instructions detailing signs and symptoms that should trigger a call to the physician.
Medication education is the second component. A pharmacist compares medications patients have been taking at home with what is ordered in the hospital, reviewing all binder information to verify the patient’s understanding of every pill’s purpose. Each day, the nurse reinforces this education. At discharge, the pharmacist reviews the medications that the patient will take at home, whom to contact if they run out, and how to reorder. “We always encourage patients to take ownership of their treatment,” says Patrice Miller, vice president for clinical resources management. “We stress the risks of not taking a medication exactly as prescribed, and what problems can occur.” The family is alerted to possible side effects and reactions.
In the third component, post-discharge follow-up, pharmacists call each patient on the second, seventh, fourteenth, twenty-first, and thirtieth day. This is a unique program aspect, Miller says; such calls are typically made by disease managers. Pharmacists confirm upcoming scheduled doctors’ visits, review all discharge instructions, and check on the patients’ understanding of their current medication regimen and adherence to time and dosage instructions.
Several times a week, pharmacists encounter a problem involving reorganizing or timing a medication, reports Joanne Heil, PharmD, RN, advanced practice heart failure specialist, who coordinates pharmacists’ calls and questions to patients. “For example, someone may skip a water pill when out all day at a social event, or say, I’ll just take it at night — I’m at work all day. We explain what can happen when they miss a day, and that taking it near bedtime interferes with the sleep they need. We work with each patient to find a specific time of day when they will have enough hours at home, away from bedtime, to take that daily water pill.”
The pilot program required no additional staff; case managers, pharmacists, and nurses received brief training. Educational binders cost about $15 per patient.
“Expenses totaled much less than the cost of a readmission,” Miller observes. Jefferson is auditing admissions and readmissions for pilot program participants. “A common cause of readmission in heart failure patients is noncompliance. The [readmission] numbers look promising,” she says, but declines to report the actual reduction.
“On June 1, we rolled out this readmission reduction approach for patients diagnosed with pneumonia. We’re building a team for myocardial infarction, to launch in December.”
“People don’t think of their insurance company as doing more than paying a claim. They don’t expect a more caring approach,” says Michael Golinkoff, MD, head of specialty clinical operations for Aetna. In the company’s behavioral view of members’ health and wellness, “Psychological factors affect whether people take their medications as prescribed. An important educational component is understanding the meaning of taking a medication.”
Savings is another consideration. “We want to avoid acute situations that send patients to emergency rooms or doctors, which is expensive,” says Golinkoff.
Aetna’s value-based insurance design (VBID) program is designed to remove financial barriers to medication compliance and encourage member participation in nurse counseling. People with chronic diseases are eligible for reduced drug copayments if they agree. “We want to support that core relationship with the nurse, who we trained to hear what the member is saying, and let that set the agenda for driving a patient’s range of services,” explains Golinkoff.
One goal of VBID is to increase adherence to drug regimens without increasing overall costs. Active Health Management, an Aetna subsidiary, administered a VBID program for a large employer. The employer reduced copayments for five classes of drugs prescribed for serious chronic conditions, including high blood pressure and asthma. Copayments for generics were lowered from $5 to zero, preferred brand drugs went from $25 to $12.50, and nonpreferred brands dropped from $45 to $22.50. All patients already taking these medications could participate.
The program increased medication adherence by 3 percent. The employer’s pharmacy costs rose by an average of $7.75 per employee per month, but costs for nondrug health care services such as hospital admissions decreased by the same amount. There was no overall increase in employer costs, and Aetna predicts that costs will have declined as a direct result of this compliance program.
The approach is being tried elsewhere. Researchers at the University of California– San Francisco and the University of Texas–Austin measured a VBID program’s effect at a large retail company. Employees with diabetes, asthma, coronary artery disease, or heart failure were offered reduced cost-sharing if they agreed to receive nurse counseling or educational materials, depending on whether they were high- or low-risk workers.
Better adherence sometimes comes down to financial incentive for the patient.
In the group receiving nurse counseling, medication adherence improved in patients taking diabetes medications, antihypertensives, and statins. After 1.5 years, the counseling group had significantly lower total overall cost compared with the control group.
Those receiving health education materials had an overall annual cost much higher than the control group.
Researchers concluded that active counseling is more effective than passive approaches for increasing appropriate health care utilization, improving clinical outcomes, and reducing total health care costs.
In a pilot program involving more than 800,000 members, Express Scripts is testing an approach called “Advanced Adherence Solutions.” Its algorithms attempt to identify members at highest risk for adherence problems.
Whenever the predictive model, operating since February, projects a risk, an automated phone system gathers additional information from the member to pinpoint that member’s barrier.
In the first 96,000 interventions, the most common difficulty (49 percent) was simply forgetting to take a medication. About 21 percent hadn’t gotten a needed renewal. Another 15 percent were concerned about a prescription’s cost. The remaining 15 percent had what Nease of Express Scripts calls “clinical questions — when a drug seems not to be working, or they are concerned about a side effect.”
Each risk-prone person is automatically directed to appropriate staff members. Most are connected to the Member Choice Center. Forgetful patients needing reminders may be sent either a “passive tracker,” such as a labeled pillbox showing whether they’ve taken their medication, or an “active tracker,” such as a beeper or a high-technology device such as a programmed blinking bottle cap. For financial difficulties, representatives suggest lower-cost drugs, a money-saving home delivery arrangement, or payment options.
Renewals are increased through auto-refill, or a new approach for patients with “silent symptoms,” as in osteoporosis or hypertension, who may forget to schedule a doctor’s visit for a renewal. “If the patient agrees, we, as a PBM, can reach out to the physician to help get a new prescription. We’re chipping away at the renewal hurdle, tracking how many prescriptions can be written without a physician visit,” Nease says.
The pilot program is reducing expenses by identifying the 85 percent with nonmedical risk factors. “This frees up our most costly resources for those requiring a pharmacist’s assistance,” Nease observes.
“Some phone conversations between a patient and a pharmacist are under 15 minutes,” reports Heather Sundar, PharmD, senior director for clinical products at Express Scripts. “But a very complex patient may need lengthy discussion and further intervention. We inform and educate them about their disease and how to manage potential side effects — but we still have nonmedical issues to address. It really comes back to behavior,” says Sundar.
Some barriers involve self-esteem. Nease cites a window of opportunity for patients new to a particular therapy, especially their first maintenance medication, typically for hypertension or hypercholesterolemia. “For a week or two, some healthy people, gradually realizing that they are on this medication forever, may resist taking it. Our approach is to give them permission to admit their difficulty.”
Pharmacists gently encourage incorporating the new medication into daily life, reassuring the patient to allow adjustment time.
“We shoot for low-cost interventions to solve problems, and expect this pilot to decrease overall costs related to therapeutic adherence,” says Nease. “As we learn more, we’ll refine the program.
Wegener, the Johns Hopkins psychologist, believes that patients decide whether to take medication through a personal cost-benefit analysis. Costs range from actual expense to side effects to mere inconvenience. Helping the patient realize the medication’s specific value and decreasing either financial or behavioral barriers — until its perceived benefits clearly outweigh any negatives — is the core of any successful approach to adherence.
A blueprint for high-volume, high-quality lung cancer screening that is detecting cancer earlier—and helping to save lives
Multiple Sclerosis: New Perspectives on the Patient Journey–2019 Update
Summary of an Actuarial Analysis and Report